EP1516049A4 - COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF LUNG CANCER - Google Patents

COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF LUNG CANCER

Info

Publication number
EP1516049A4
EP1516049A4 EP02739247A EP02739247A EP1516049A4 EP 1516049 A4 EP1516049 A4 EP 1516049A4 EP 02739247 A EP02739247 A EP 02739247A EP 02739247 A EP02739247 A EP 02739247A EP 1516049 A4 EP1516049 A4 EP 1516049A4
Authority
EP
European Patent Office
Prior art keywords
diagnosis
compositions
treatment
methods
lung cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02739247A
Other languages
German (de)
French (fr)
Other versions
EP1516049A2 (en
Inventor
Michael J Lodes
Tongtong Wang
Liqun Fan
Paul A Algate
Patricia D Mcneill
Robert A Henderson
Raodoh Moahamath
Heather Secrist
Darin R Benson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/854,133 external-priority patent/US6759508B2/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of EP1516049A2 publication Critical patent/EP1516049A2/en
Publication of EP1516049A4 publication Critical patent/EP1516049A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP02739247A 2001-05-11 2002-05-10 COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF LUNG CANCER Withdrawn EP1516049A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US854133 2001-05-11
US09/854,133 US6759508B2 (en) 2000-09-01 2001-05-11 Compositions and methods for the therapy and diagnosis of lung cancer
PCT/US2002/014975 WO2002092001A2 (en) 2001-05-11 2002-05-10 Compositions and methods for the therapy and diagnosis of lung cancer

Publications (2)

Publication Number Publication Date
EP1516049A2 EP1516049A2 (en) 2005-03-23
EP1516049A4 true EP1516049A4 (en) 2006-01-11

Family

ID=25317820

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02739247A Withdrawn EP1516049A4 (en) 2001-05-11 2002-05-10 COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF LUNG CANCER

Country Status (3)

Country Link
EP (1) EP1516049A4 (en)
AU (1) AU2002311909A1 (en)
WO (1) WO2002092001A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
US7226791B2 (en) * 2003-06-02 2007-06-05 Bristol-Myers Squibb Company Polynucleotides encoding novel guanylate binding proteins (GBP's)
PT2322221E (en) 2008-08-05 2014-09-19 Toray Industries Pharmaceutical composition for treatment and prevention of cancer
BRPI0911925B8 (en) * 2008-08-05 2024-02-06 Toray Industries Method to detect cancer
PL2532364T3 (en) 2010-02-04 2016-11-30 Pharmaceutical composition comprising anti caprin-1 antibodies for treating and/or preventing cancer
KR101805520B1 (en) 2010-02-04 2017-12-07 도레이 카부시키가이샤 Pharmaceutical composition for treatment and/or prevention of cancer
CA2788716C (en) 2010-02-04 2019-06-18 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
ES2583627T3 (en) 2010-02-04 2016-09-21 Toray Industries, Inc. Pharmaceutical composition for the treatment and / or prevention of cancer
US8709418B2 (en) 2010-02-04 2014-04-29 Toray Industries, Inc. Pharmaceutical composition for treating CAPRIN-1 expressing cancer
BR112012018943A8 (en) 2010-02-04 2017-12-19 Toray Industries medicine and method for treating and / or preventing cancer
WO2013018886A1 (en) 2011-08-04 2013-02-07 東レ株式会社 Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
HUE030137T2 (en) 2011-08-04 2017-04-28 Toray Industries Cancer treatment and/or prevention drug composition
ES2634249T3 (en) 2011-08-04 2017-09-27 Toray Industries, Inc. Pharmaceutical composition for the treatment and / or prophylaxis of cancer
PT2741085T (en) 2011-08-04 2017-06-30 Toray Industries Method for detecting pancreatic cancer
RU2595400C2 (en) 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Pharmaceutical composition for treating and/or preventing malignant growth
RU2624049C2 (en) 2011-08-04 2017-06-30 Торэй Индастриз, Инк. Pharmaceutical composition for cancer treatment and prevention
MX348578B (en) 2011-08-04 2017-06-20 Toray Industries Pharmaceutical composition for treatment and/or prophylaxis of cancer.
EP2818483B1 (en) 2012-02-21 2017-08-02 Toray Industries, Inc. Medicinal composition for treating and/or preventing cancer
MX360211B (en) 2012-02-21 2018-10-24 Toray Industries Pharmaceutical composition for treatment and/or prevention of cancer.
CA2864999C (en) 2012-02-21 2020-06-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
US9273130B2 (en) 2012-02-21 2016-03-01 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
CN104220095B (en) 2012-03-30 2016-09-07 东丽株式会社 The treatment of liver cancer and/or prophylactic compositions
CA2869123C (en) 2012-03-30 2021-03-16 Toray Industries, Inc. Pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment of gallbladder cancer
PL2876447T3 (en) 2012-07-19 2020-05-18 Toray Industries, Inc. Method for detecting cancer
EP2876446B1 (en) 2012-07-19 2018-12-26 Toray Industries, Inc. Method for detecting cancer
EP3031826B1 (en) 2013-08-09 2018-10-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000828A2 (en) * 1999-06-30 2001-01-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2001072295A2 (en) * 2000-03-29 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2001096390A2 (en) * 2000-06-09 2001-12-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968770A (en) * 1995-02-10 1999-10-19 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd523 as a target

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000828A2 (en) * 1999-06-30 2001-01-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2001072295A2 (en) * 2000-03-29 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2001096390A2 (en) * 2000-06-09 2001-12-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 2 May 2001 (2001-05-02), "Homo sapiens cystine/glutamate transporter xCT mRNA", XP002337270, retrieved from EBI Database accession no. AF252872 *
DATABASE EMBL 5 August 1999 (1999-08-05), "Seq ID no: 3414", XP002337271, retrieved from EBI Database accession no. AAZ15945 *
DATABASE EMBL XP002337272, retrieved from EBI Database accession no. AAZ12811 *

Also Published As

Publication number Publication date
WO2002092001A3 (en) 2005-01-13
EP1516049A2 (en) 2005-03-23
AU2002311909A1 (en) 2002-11-25
WO2002092001A2 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
EP1516049A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF LUNG CANCER
EP1692318A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF LUNG CANCER
EP1515982A4 (en) METHODS AND COMPOSITIONS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER
EP1639090A4 (en) COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING CANCER
EP1583504A4 (en) METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS, AND TREATMENT OF CANCER
EP1589933A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF A TUMOR
NO20016427D0 (en) Compositions and Methods for the Treatment of Diagnosis of Lung Cancer
EP1578371A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS
EP1572091A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS
EP1553912A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF A TUMOR
EP1578380A4 (en) COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER
EP1438062A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF SKIN LESIONS
EP1578347A4 (en) COMPOSITIONS AND METHODS FOR THE DETECTION, DIAGNOSIS AND THERAPY OF HEMATOLOGICAL MALIGNITES
EP1578385A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF INFLAMMATORY INTESTINAL DISEASES
EP1539251A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF DISEASES INVOLVING ANGIOGENESIS
EP1590433A4 (en) DIAGNOSIS AND PROGNOSIS OF PATIENTS SUFFERING FROM BREAST CANCER
EP1575571A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A TUMOR
EP1756137A4 (en) DIAGNOSTIC AND THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING PTEN AND BREAST CANCER
EP1578354A4 (en) TARGETS, METHODS AND REAGENTS FOR THE DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA
EP1446013A4 (en) COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF LUNG CANCER
EP1499328A4 (en) METHODS OF TREATING NEONATAL NECROSANT ENTEROCOLITIS
EP1889058A4 (en) DIAGNOSIS AND TREATMENT OF ENDOMETRIOSIS
EP1756166A4 (en) DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
EP1608967A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS
EP1626711A4 (en) COMPOSITIONS AND METHODS FOR ANTICANCER TREATMENT

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031211

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1075674

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20051123

17Q First examination report despatched

Effective date: 20061110

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090122

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1075674

Country of ref document: HK